| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 1999;68:2021-2024
© 1999 The Society of Thoracic Surgeons
a Division of Thoracic Surgery and Department of Medicine (Gastroenterology Division), University of Maryland School of Medicine and Veterans Affairs Hospital, Greenebaum Cancer Center, Baltimore, Maryland, USA
Address reprint requests to Dr Krasna, Division of Thoracic Surgery, University of Maryland Medical Center, 22 South Greene St, Room N4W94, Baltimore, MD 21201
e-mail: mkrasna{at}surgery1.ab.umd.edu
Presented at the Thirty-fifth Annual Meeting of The Society of Thoracic Surgeons, San Antonio, TX, Jan 25–27, 1999.
Abstract
Background. P53 protein overexpression in esophageal cancer and its correlation with response and survival after chemoradiation was retrospectively investigated.
Methods. Pretreatment and resection specimens were stained by automatic p53 immunohistochemical staining technique.
Results. P53 was expressed in 84.0% of esophagoscopy (EGD) biopsies; 71.4% of patients with metastasis of thoracoscopy/laparoscopy lymph nodes (TS/LS LN) identified by hematoxylin/eosin (H/E) were p53 (+); 14.2% of patients with negative TS/LS LN by H/E were p53 (+). Eleven out of 18 patients with p53 (+) in pretreatment EGD remained p53 (+) after chemoradiation; 38.8% of these patients had a pathological complete response (pCR). The median survival of this group was 15 months. Of 4 patients with p53 (-) pretreatment EGD, all of those were still p53 (-) after chemoradiation; 75% of these patients had pCR. The median survival was 30 months. In patients with p53 (+) TS/LS LN, 23% had a pCR after chemoradiation with a median survival of 16 months. In patients with p53 (-) TS/LS LN, 50.0% had a pCR with a median survival of 31.5 months.
Conclusions. P53 protein overexpression in pretreatment EGD and TS/LS LN may predict response to chemoradiation and survival in esophageal cancer patients.
This article has been cited by other articles:
|
|
 |
|
  X. Jiao, A. Eslami, O. Ioffe, K. F. Kwong, M. Henry, Q. Zeng, Y. Refaely, W. Burrows, Z. Gamliel, and M. J. Krasna Immunohistochemistry analysis of micrometastasis in pretreatment lymph nodes from patients with esophageal cancer Ann. Thorac. Surg., October 1, 2003; 76(4): 996 - 1000. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. G. Casson, S. C. Evans, A. Gillis, G. A. Porter, P. Veugelers, S. J. Darnton, D. L. Guernsey, and P. Hainaut Clinical implications of p53 tumor suppressor gene mutation and protein expression in esophageal adenocarcinomas: Results of a ten-year prospective study J. Thorac. Cardiovasc. Surg., May 1, 2003; 125(5): 1121 - 1131. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Noguchi, S. Takeno, T. Shibata, Y. Uchida, S. Yokoyama, and W. Muller Expression of heat shock protein 70 in grossly resected esophageal squamous cell carcinoma Ann. Thorac. Surg., July 1, 2002; 74(1): 222 - 226. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Jiao and M. J. Krasna Clinical significance of micrometastasis in lung and esophageal cancer: a new paradigm in thoracic oncology Ann. Thorac. Surg., July 1, 2002; 74(1): 278 - 284. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Krasna, X. Jiao, J. R. Sonett, Z. Gamliel, A. Eslami, Y. Raefaly, and Y. Mao Thoracoscopic and laparoscopic lymph node staging in esophageal cancer: do clinicopathological factors affect the outcome? Ann. Thorac. Surg., June 1, 2002; 73(6): 1710 - 1713. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Krasna, C. E. Reed, D. Nedzwiecki, D. R. Hollis, J. D. Luketich, M. M. DeCamp, R. J. Mayer, and D. J. Sugarbaker CALGB 9380: a prospective trial of the feasibility of thoracoscopy/laparoscopy in staging esophageal cancer Ann. Thorac. Surg., April 1, 2001; 71(4): 1073 - 1079. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
